Literature DB >> 30853659

Discovery and validation an eight-biomarker serum gene signature for the diagnosis of steroid-induced osteonecrosis of the femoral head.

Taixian Li1, Yanqiong Zhang2, Rongtian Wang3, Zhipeng Xue3, Shangzhu Li4, Yuju Cao5, Daobing Liu3, Yanfang Niu3, Xia Mao2, Xiaoyue Wang2, Weijie Li2, Qiuyan Guo2, Minqun Guo2, Na Lin6, Weiheng Chen7.   

Abstract

Steroid-induced osteonecrosis of the femoral head (SONFH) is difficult to be diagnosed at the early stages when it can be administrated effectively. Yet, to date no study has been performed to identify diagnostic biomarkers and to develop diagnostic models for SONFH. In the current study, a total of 60 SONFH patients with Association Research Circulation Osseous (ARCO) stages I-IV, and 20 controls were enrolled and divided into the discovery and validation cohorts. The serum samples were collected and the gene expression profiles were detected by microarray analysis based on the discovery cohort. Then, eight genes (BIRC3, CBL, CCR5, LYN, PAK1, PTEN, RAF1 and TLR4) were identified as the candidate serum biomarkers of SONFH due to the significant differential expression patterns and the topological importance in the interaction network of SONFH-related differentially expressed genes. Functionally, these candidate serum biomarkers were significantly involved into several pathological processes during SONFH progression, such as the immune regulation and inflammation, bone metabolism and angiogenesis. After that, a prediction model for the diagnosis of SONFH was constructed using Partial least squares regression based on the serum levels of the candidate biomarkers. Notably, both the 10-fold cross-validation and the independent dataset test demonstrated the good performance of this model. In conclusion, our study discovered eight promising serum biomarkers and developed the multi-biomarker-based prediction model as a new, potential and non-invasive diagnostic tool for the detection of SONFH, as well as benefit the administration of SONFH in a daily clinical setting.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biological molecular network; Biomarker; Gene expression profiling; Partial least square model; Steroid-induced osteonecrosis of the femoral head

Mesh:

Substances:

Year:  2019        PMID: 30853659     DOI: 10.1016/j.bone.2019.03.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  10 in total

Review 1.  Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update.

Authors:  Michael A Mont; Hytham S Salem; Nicolas S Piuzzi; Stuart B Goodman; Lynne C Jones
Journal:  J Bone Joint Surg Am       Date:  2020-06-17       Impact factor: 6.558

2.  PARK7 promotes repair in early steroid-induced osteonecrosis of the femoral head by enhancing resistance to stress-induced apoptosis in bone marrow mesenchymal stem cells via regulation of the Nrf2 signaling pathway.

Authors:  Fei Zhang; Yanglin Yan; Wuxun Peng; Lei Wang; Tao Wang; Zhihong Xie; Hong Luo; Jian Zhang; Wentao Dong
Journal:  Cell Death Dis       Date:  2021-10-13       Impact factor: 8.469

3.  General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19.

Authors:  Wenlong Li; Zeqing Huang; Biao Tan; Gang Chen; Xugui Li; Kan Xiong; Ruizheng Zhu; Ruihan Li; Shuwen Li; Hengli Ye; Zhi Liang; Xiaojun Dong; Shijing Zhou; Song Chen; Haixiang Xi; Hao Cheng; Rongpeng Xu; Shenghao Tu; Zhe Chen; Lihua Qi; Jiandong Song; Ruoran Xiao; Huilan Liu; Qian Nan; Huiyong Yu; Hongsheng Cui; Yanguang Shen; Chengxiang Wang; Na Lin; Yanqiong Zhang; Weiheng Chen
Journal:  J Orthop Translat       Date:  2021-10-20       Impact factor: 5.191

Review 4.  Steroid-Induced Osteonecrosis of the Femoral Head: Novel Insight Into the Roles of Bone Endothelial Cells in Pathogenesis and Treatment.

Authors:  Cheng Huang; Zeqin Wen; Junjie Niu; Subin Lin; Weiguo Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-30

5.  Identification of potential autophagy-related genes in steroid-induced osteonecrosis of the femoral head via bioinformatics analysis and experimental verification.

Authors:  Xue-Zhen Liang; Di Luo; Yan-Rong Chen; Jia-Cheng Li; Bo-Zhao Yan; Yan-Bo Guo; Ming-Tao Wen; Bo Xu; Gang Li
Journal:  J Orthop Surg Res       Date:  2022-02-12       Impact factor: 2.359

6.  Cyclic Polypeptide D7 Protects Bone Marrow Mesenchymal Cells and Promotes Chondrogenesis during Osteonecrosis of the Femoral Head via Growth Differentiation Factor 15-Mediated Redox Signaling.

Authors:  Jiazheng Chen; Zichen Cui; Yi Wang; Linmao Lyu; Changgong Feng; Dianjie Feng; Yifan Cheng; Ziqing Li; Shui Sun
Journal:  Oxid Med Cell Longev       Date:  2022-03-03       Impact factor: 6.543

7.  Osteogenesis-Related Long Noncoding RNA GAS5 as a Novel Biomarker for Osteonecrosis of Femoral Head.

Authors:  Guanzhi Liu; Sen Luo; Yutian Lei; Ming Jiao; Ruomu Cao; Huanshuai Guan; Run Tian; Kunzheng Wang; Pei Yang
Journal:  Front Cell Dev Biol       Date:  2022-03-22

8.  Identification of Inflammation-Related Genes and Exploration of Regulatory Mechanisms in Patients with Osteonecrosis of the Femoral Head.

Authors:  Tong Li; Cheng Huang; Jinhui Ma; Ran Ding; Qidong Zhang; Weiguo Wang
Journal:  Biomed Res Int       Date:  2022-09-22       Impact factor: 3.246

9.  PTEN inhibitor VO-OHpic attenuates GC-associated endothelial progenitor cell dysfunction and osteonecrosis of the femoral head via activating Nrf2 signaling and inhibiting mitochondrial apoptosis pathway.

Authors:  Xudong Yao; Shengnan Yu; Xingzhi Jing; Jiachao Guo; Kai Sun; Fengjing Guo; Yaping Ye
Journal:  Stem Cell Res Ther       Date:  2020-03-30       Impact factor: 6.832

10.  Identification of key biomarkers in steroid-induced osteonecrosis of the femoral head and their correlation with immune infiltration by bioinformatics analysis.

Authors:  Jun Zhao; Xingshi Zhang; Junjie Guan; Yu Su; Jizhao Jiang
Journal:  BMC Musculoskelet Disord       Date:  2022-01-18       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.